Cellectis Bets Everything on Unproven In Vivo Gene Editing With Clock Ticking

Cellectis Pivots to In Vivo Gene Editing, Exits Cell Therapy

Cellectis has announced a strategic transformation to become an in vivo gene editing company, shifting its focus to developing long-lasting treatments for chronic diseases. This pivot involves advancing two lead in vivo programs, .HEAL-101 for severe hypertriglyceridemia and .HEAL-201 for severe hypercholesterolemia, with preliminary Phase 1 data expected in H2 2027 and H1 2028, respectively. Concurrently, the company will exit the development of its allogeneic CAR T-cell therapies, lasme-cel and eti-cel, due to an evolving competitive landscape. This realignment aims to extend Cellectis' cash runway into H2 2028, supported by continuing existing cell therapy partnerships.

• Cellectis is prioritizing its in vivo gene editing pipeline, with lead candidates .HEAL-101 and .HEAL-201. .HEAL-101 targets APOC3 for severe hypertriglyceridemia, while .HEAL-201 targets PCSK9 for severe hypercholesterolemia. Both programs have shown promising preclinical proof-of-concept, with Phase 1 investigator-initiated trials planned in China and preliminary data anticipated in H2 2027 for .HEAL-101 and H1 2028 for .HEAL-201.
• The company is discontinuing the development of its allogeneic CAR T-cell therapies, lasme-cel and eti-cel, for B-ALL and NHL. This decision stems from a thorough assessment of the changing therapeutic landscape, including lower relapse rates with frontline treatments and increased competition from bispecific antibodies and in vivo CAR-T approaches, which have reduced the addressable patient population and extended development timelines.
• To support the strategic shift, Cellectis is realigning its operational model and resources. This includes maintaining existing cell therapy partnerships with AstraZeneca, Allogene, Servier, and Iovance. These actions are designed to extend the company's cash runway into the second half of 2028, providing financial flexibility to advance the in vivo gene editing pipeline through critical development milestones.

The Unmet Needs Driving Cellectis' Focus on Severe Hypertriglyceridemia

Severe hypertriglyceridemia (sHTG) represents a high-burden metabolic disorder with substantial unmet need, driven by the inadequacy of conventional therapies — including fibrates, omega-3 fatty acids, and niacin — to achieve sufficient triglyceride (TG) reduction and prevent life-threatening acute pancreatitis (AP). The populations most acutely underserved are those with familial chylomicronemia syndrome (FCS) and multifactorial or persistent chylomicronemia syndromes (MCS, pCS), where recurrent, potentially fatal AP episodes remain a persistent clinical challenge.

• Patients with FCS and complete absence of lipoprotein lipase (LPL) activity: FCS, caused by biallelic loss-of-function variants in LPL, GPIHBP1, APOA5, APOC2, or LMF1, results in TG levels >10 mmol/L from childhood. Existing lipid-lowering therapies are minimally effective in this population, and angiopoietin-like protein 3 (ANGPTL3) inhibitors — which require at least partial LPL activity — have been found not to lower plasma TG in patients with FCS who completely lack LPL activity, leaving a critical therapeutic gap.

• Patients with sHTG at high risk of recurrent acute pancreatitis: sHTG is associated with a higher mortality rate, increased incidence of pancreatic necrosis, greater need for intensive care, and longer duration of hospitalization relative to other causes of AP. Most patients with severe hypertriglyceridemia do not achieve adequate TG control with lifestyle interventions or conventional lipid-lowering therapies, leaving them exposed to persistent complications including recurrent AP, chronic pancreatitis, diabetes mellitus, and organ failure.

• Patients requiring TG reductions beyond what conventional therapies can deliver: Recent analyses of randomized controlled trials with approved apolipoprotein C-III (apoC-III)-targeting drugs show that lowering TG levels by ≥40% is associated with lower AP risk — a threshold that standard therapies often fail to reach. Apolipoprotein C-III (apoC-III) inhibitors, including volanesorsen, olezarsen, and plozasiran, have demonstrated up to 80% reductions in TG and markedly lower AP incidence, addressing the unmet need for more potent, mechanism-targeted intervention.

• Patients with drug-induced safety concerns under existing RNA-targeted therapies: Among apoC-III inhibitors, olezarsen and plozasiran are identified as safer alternatives to volanesorsen with respect to the risk of drug-induced thrombocytopenia in patients with FCS or severe HTG, highlighting an unmet need for efficacious therapies with improved tolerability profiles in this vulnerable population.

• Genetically confirmed but underdiagnosed patients: Rare genetic variants — such as compound heterozygous LMF1 variants, which account for only 1% of FCS cases — contribute to the FCS phenotype through decreased lipase activity and mass. This underscores the unmet need for improved genetic characterization and specialist referral to identify patients who may benefit from emerging targeted therapies.

Navigating the Competitive Landscape for APOC3 Gene Editing

The knowledge base does not have sufficient information to answer this question.

Where Cellectis' Gene Editing Fits in the Evolving Severe Hypertriglyceridemia Landscape

Over the past five years, the treatment landscape for severe hypertriglyceridemia (sHTG) has shifted markedly from conventional lipid-lowering agents — fibrates, omega-3 fatty acids, and lipoprotein apheresis — toward mechanism-based molecular therapies targeting key regulators of triglyceride metabolism. Apolipoprotein C-III (ApoC-III) inhibition has emerged as a central therapeutic strategy. Volanesorsen, a second-generation 2'-O-methoxyethyl antisense oligonucleotide, received European Medicines Agency approval as an adjunct to diet in adult familial chylomicronemia syndrome (FCS) patients with an inadequate response to triglyceride-lowering therapy, demonstrating reductions from >5000 mg/dL to 350–500 mg/dL at 12 months in at least one reported case, with cessation of lipoprotein apheresis and no episodes of pancreatitis. Its successor, olezarsen — an N-acetylgalactosamine (GalNAc)-conjugated antisense oligonucleotide — inhibits hepatic ApoC-III through both lipoprotein lipase (LPL)-dependent and -independent pathways. In the Phase 3 BALANCE trial, olezarsen reduced fasting triglycerides by approximately 60% at 12 months in FCS patients, with a marked decrease in pancreatitis events versus placebo, and demonstrated triglyceride reductions of around 50% in moderate and severe hypertriglyceridemia. The CORE-TIMI 72a and CORE2-TIMI 72b trials further showed that olezarsen markedly lowered triglycerides and reduced the risk of acute pancreatitis in patients with sHTG. A matching-adjusted indirect comparison of olezarsen versus volanesorsen in FCS found no statistically significant differences in fasting triglycerides, ApoC-III, acute pancreatitis events, or adverse events at 52 weeks, though olezarsen demonstrated a more favorable tolerability profile, with most adverse events limited to mild injection-site reactions and no clinically significant thrombocytopenia — in contrast to the thrombocytopenia risk associated with volanesorsen.

Angiopoietin-like 3 (ANGPTL3) inhibition via evinacumab has also been evaluated in sHTG across two phase 2 trials. A randomized trial across three cohorts — familial chylomicronemia syndrome with bi-allelic loss-of-function LPL pathway mutations, multifactorial chylomicronemia syndrome with heterozygous loss-of-function mutations, and multifactorial chylomicronemia syndrome without LPL pathway mutations — found that evinacumab 15 mg/kg every 4 weeks reduced triglycerides in cohort 3 by a mean of -27.1% (s.e.m. 37.4; 95% CI -71.2 to 84.6), though the prespecified primary endpoint was not met. A subsequent phase 2b study (NCT04863014) evaluated evinacumab 20 mg/kg intravenously every 4 weeks in patients with sHTG and a history of hypertriglyceridemia-associated acute pancreatitis, finding a median percentage change in triglycerides from baseline to week 4 of -55.3% with evinacumab versus +1.5% with placebo, with a 95.7% reduction by week 16. However, the proportion of patients with at least one positively adjudicated acute pancreatitis episode during the 52-week treatment period was 27.3% with evinacumab versus 10.0% with placebo, with all adjudicated episodes occurring ≥58 days after the last evinacumab dose. The data suggested evinacumab may be efficacious in lowering triglyceride concentrations, though the sample size was too small to determine whether it can prevent acute pancreatitis. Notably, a 2023 review identified evinacumab as among the drugs abandoned for sHTG treatment, alongside vupanorsen.

Beyond ApoC-III and ANGPTL3 inhibition, additional therapeutic modalities are in development. Plozasiran, an siRNA targeting APOC3, has shown up to 80% reductions in triglycerides with markedly lower acute pancreatitis incidence and favorable safety profiles. A novel triple agonist, DR10624, demonstrated rapid and significant reductions in triglycerides and liver fat in patients with sHTG in a phase 2 trial presented at the 2025 American Heart Association Scientific Sessions. FGF21 analogs such as pegozafermin are in early development, though their impact on acute pancreatitis prevention remains to be established. Lomitapide, acting independently of LPL, has shown efficacy in selected FCS patients but requires careful hepatic monitoring. Despite these advances, a 2023 review noted that the ultimate clinical goal — a definitive decrease in the risk of acute pancreatitis — had not been definitively achieved by any approved or investigational pharmacotherapy at that time, underscoring that ongoing studies will be required to clarify long-term safety, durability of response, and optimal patient selection.

Cellectis' Strategic Pivot: Gene Editing for Chronic Metabolic Diseases

Cellectis' recent announcement signals a profound strategic realignment, shifting its core focus from allogeneic CAR T-cell therapies to in vivo gene editing for chronic diseases. This pivot is a calculated response to the evolving competitive landscape and inherent challenges within the CAR T-cell space. While allogeneic CAR T-cells have shown promise in certain hematological malignancies, studies indicate significant hurdles, including the risk of graft-versus-host disease (GVHD), limited cell persistence, and complex manufacturing logistics, which collectively impact their broad applicability and cost-effectiveness.

By discontinuing its CAR T-cell programs, Cellectis is de-risking its portfolio and redirecting its gene editing expertise towards a new frontier: long-lasting treatments for chronic metabolic disorders. The company's lead programs, .HEAL-101 and .HEAL-201, target severe hypertriglyceridemia and hypercholesterolemia, respectively. These conditions represent significant unmet medical needs, and the chosen targets, such as ANGPTL3 and ApoC-III, are well-validated. Research shows that inhibiting these proteins can effectively reduce triglyceride and LDL cholesterol levels, offering a compelling therapeutic strategy.

This strategic move carries several implications and considerations:

• Leveraging Core Competency: Cellectis is applying its foundational gene editing technology, previously used in CAR T-cell engineering, to a new modality that promises durable, potentially 'one-and-done' treatments for chronic conditions.

• Addressing Unmet Needs: Targeting severe lipid disorders with a gene editing approach could offer a transformative solution for patients who require lifelong management with current therapies.

• Early-Stage Development Risk: The new programs are in very early stages, with initial Phase 1 data not expected for several years. This introduces a substantial timeline and clinical development risk.

• Competitive Landscape: While promising, the field of gene editing for metabolic diseases is attracting significant investment. Furthermore, other modalities like antisense oligonucleotides (e.g., olezarsen for APOC3) are already demonstrating clinical efficacy, creating a competitive environment for long-term lipid management.

• Technical Hurdles: The successful translation of in vivo gene editing, particularly concerning delivery efficiency, potential off-target effects, and immunogenicity, remains a critical challenge that will need to be thoroughly addressed in clinical trials.

Ultimately, this pivot reflects a strategic bet on the long-term potential of in vivo gene editing to deliver transformative, durable therapies for chronic diseases, while also extending the company's cash runway. The success of this strategy will hinge on the clinical validation of its early-stage programs and its ability to navigate the technical and competitive landscape of gene therapy.